Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, Besemer B, Dürig J, Schroers R, von Metzler I, Hänel M, Mann C, Asemissen AM, Heilmeier B, Weinhold N, Huhn S, Kriegsmann K, Luntz SP, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Khandanpour C, Knauf W, Scheid C, Munder M, Geer T, Riesenberg H, Thomalla J, Hoffmann M, Raab MS, Salwender HJ, Weisel KC; German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators. Goldschmidt H, et al. Among authors: besemer b. Lancet Haematol. 2022 Nov;9(11):e810-e821. doi: 10.1016/S2352-3026(22)00263-0. Lancet Haematol. 2022. PMID: 36328040 Clinical Trial.
Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial.
Weisel KC, Scheid C, Zago M, Besemer B, Mai EK, Haenel M, Duerig J, Munder M, Lindemann HW, Seckinger A, Kunz C, Benner A, Hose D, Jauch A, Salwender H, Goldschmidt H. Weisel KC, et al. Among authors: besemer b. Blood Cancer J. 2019 Apr 8;9(4):45. doi: 10.1038/s41408-019-0206-8. Blood Cancer J. 2019. PMID: 30962424 Free PMC article. Clinical Trial. No abstract available.
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.
Goldschmidt H, Baertsch MA, Schlenzka J, Becker N, Habermehl C, Hielscher T, Raab MS, Hillengass J, Sauer S, Müller-Tidow C, Luntz S, Jauch A, Hose D, Seckinger A, Brossart P, Goerner M, Klein S, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Haenel M, Martin H, Lindemann HW, Scheid C, Nogai A, Salwender H, Noppeney R, Besemer B, Weisel K; German Myeloma Multicenter Group (GMMG). Goldschmidt H, et al. Among authors: besemer b. Leukemia. 2021 Apr;35(4):1134-1144. doi: 10.1038/s41375-020-0948-0. Epub 2020 Jul 21. Leukemia. 2021. PMID: 32694619 Clinical Trial.
Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment.
Kriegsmann K, Hundemer M, Hofmeister-Mielke N, Reichert P, Manta CP, Awwad MHS, Sauer S, Bertsch U, Besemer B, Fenk R, Hänel M, Munder M, Weisel KC, Blau IW, Neubauer A, Müller-Tidow C, Raab MS, Goldschmidt H, Huhn S, For The German-Speaking Myeloma Multicenter Group Gmmg. Kriegsmann K, et al. Among authors: besemer b. Cancers (Basel). 2020 Aug 18;12(8):2322. doi: 10.3390/cancers12082322. Cancers (Basel). 2020. PMID: 32824635 Free PMC article.
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
Baertsch MA, Mai EK, Hielscher T, Bertsch U, Salwender HJ, Munder M, Fuhrmann S, Dührsen U, Brossart P, Neben K, Schlenzka J, Kunz C, Raab MS, Hillengaß J, Jauch A, Seckinger A, Hose D, Luntz S, Sonneveld P, Lokhorst H, Martin H, Goerner M, Hoffmann M, Lindemann HW, Bernhard H, Blau IW, Scheid C, Besemer B, Weisel KC, Hänel M, Dürig J, Goldschmidt H; German-Speaking Myeloma Multicenter Group (GMMG). Baertsch MA, et al. Among authors: besemer b. Blood Cancer J. 2021 Jan 7;11(1):1. doi: 10.1038/s41408-020-00390-3. Blood Cancer J. 2021. PMID: 33414374 Free PMC article. Clinical Trial.
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial.
Salwender H, Elmaagacli A, Merz M, Miah K, Benner A, Haenel M, Jehn C, Mai EK, Bertsch U, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Raab MS, Luntz SP, Besemer B, Munder M, Brossart P, Fuhrmann S, Lindemann HW, Weisel K, Duerig J, Goldschmidt H. Salwender H, et al. Among authors: besemer b. Leukemia. 2021 Oct;35(10):3007-3011. doi: 10.1038/s41375-021-01298-y. Epub 2021 May 24. Leukemia. 2021. PMID: 34031532 Clinical Trial. No abstract available.
36 results